Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats

British Journal of Pharmacology

Volumn 127, Issue 6, 1999, Pages 1454-1462

  Courteix, Christine ^a   Coudoré Civiale, Marie Ange ^a   Privat, Anne Marie ^a   Zajac, Jean Marie ^c   Eschalier, Alain ^b   Fialip, Joseph ^a  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CNRS   (France)

Author keywords

and opioid; Chronic pain; Diabetic rats; Intrathecal; Mononeuropathic rats; Morphine analgesia; Neuropathy; Neuropeptide FF

Indexed keywords

1DME; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; MORPHINE; MU OPIATE RECEPTOR; NALTRINDOLE; NEUROPEPTIDE FF; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; HYPERALGESIA; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESIA; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HYPERALGESIA; INJECTIONS, SPINAL; MALE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NERVOUS SYSTEM DISEASES; OLIGOPEPTIDES; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN; TIME FACTORS; VOCALIZATION, ANIMAL;

EID: 0032772804     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702682     Document Type: Article

References (55)

1. Advokat, C. & Gulati, A. (1991). Spinal transection reduces both spinal antinociception and CNS concentration of systematically administered morphine in rats. Brain Res., 555, 251-258.
2. Advokat, C. & Rhein, F.Q. (1995). Potentiation of morphine-induced antinociception in acute spinal rats by the NMDA antagonist dextrorphan. Brain Res., 699, 157-160.
3. Allard, M., Geoffre, S., Legendre, P., Vincent, J.D. & Simonnet, G. (1989). Characterization of rat spinal cord receptors to FLFQPQRFarnide, a mammalian morphine modulating peptide: a binding study. Brain Res., 500, 169-176.
4. Allard, M., Jordan, D., Zajac, J.-M., Ris, C., Martin, D., Monkuango, D., Kopp, N. & Simonnet, G. (1994). Autoradiography localization of receptors for neuropeptide FF, FLFQPQRFamide, in human spinal sensory system. Brain Res., 633, 127-132.
5. Allard, M., Theodosis, D.T., Rousselot, P., Lombard, M.C. & Simonnet, G. (1991). Characterization and localization of a putative morphine-modulating peptide, FLFQPQRFamide, in the rat spinal cord: biochemical and immunocytochemical studies. Neuroscience, 49, 81-92.
6. Attal, N., Chen, Y.L., Kayser, V. & Guilbaud, G. (1991). Behavioural evidence that systemic morphine may modulate a phasic pain-related behaviour in a rat model of peripheral mononeuropathy. Pain, 47, 65-70.
7. Bennett, G.J. & Xie, Y.K. (1988). A peripheral mononeuropathy in rat that produces pain disorders like those seen in man. Pain, 33, 87-107.
8. Calcagnetti, D.J. & Holtzman, G. (1991). Delta opioid antagonist, Naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or Morphine. Pharmacol. Biochem. Behav., 38, 185-190.
9. Catheline, G., Kayser, V. & Guilbaud, G. (1996). Further evidence for peripheral component in the enhanced antinociceptive effect of systemic morphine in mononeuropathic rats: involvement of kappa-, but not delta-opioid receptors. Eur. J. Pharmacol., 315, 135-143.
10. Coudoré-Civiale, M.-A., Courteix, C., Eschalier, A. & Fialip, J. (1998). Effect of tachykinin receptor antagonists in experimental neuropathic pain. Eur. J. Pharmacol., 361, 175-184.
11. Courteix, C., Bardin, M., Chantelauze, C., Lavarenne, J. & Eschalier, A. (1994). Study of the pharmacological sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain, 57, 153-160.
12. Courteix, C., Bourget, P., Caussade, F., Bardin, M., Coudore, F., Fialip, J. & Eschalier, A. (1998). Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J. Pharmacol. Exp. Ther., 285, 63-70.
13. Courteix, C., Coudore, M.-A., Eschalier, A., Fialip, J., Zajac, J.M. & Lavarenne, J. (1997). CI988, an antagonist of cholecystokinin type B receptor and 1DMe, an analogue of neuropeptide FF, enhance the analgesic effect of morphine in diabetic rats. Br. J. Pharmacol., 122 (Suppl)., 335P.
14. Courteix, C., Eschalier, A. & Lavarenne, J. (1993a). Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain, 53, 81-88.
15. Courteix, C., Lavarenne, J. & Eschalier, A. (1993b). RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur. J. Pharmacol., 241, 267-270.
16. Desmeules, J.A., Kayser, V. & Guilbaud, G. (1993). Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain, 53, 277-285.
17. Desprat, C. & Zajac, J.M. (1994). Ontogeny of neuropeptide FF pharmacology and receptors in mouse brain. Dev. Brain Res., 82, 118-126.
18. Dickenson, A.H. (1994). Neurophysiology of opioid poorly responsive pain. Cancer Surveys, 21, 5-17.
19. Drower, E.J., Stapelfeld A., Rafferty, M.F., De Costa, B.R., Rice, K.C. & Hammond, D.L. (1991). Selective antagonism by Naltrindole of the antinociceptive effects of the Delta opioid agonist cyclic(D-Penicillamine-D-Penicillamine5)enkephalin in the rat. J. Pharmacol. Exp. Ther., 259, 725-731.
20. Faris, P.I., (1985). Opiate antagonistic function of cholecystokinin in analgesia and energy balance systems. Ann. N.Y. Acad. Sci., 448, 437-447.
21. Gicquel, S., Mazarguil, H., Allard, M., Si Monnet, G. & Zajac, J.-M. (1992). Analogues F8Famide resistant to degradation, possessing high affinity and in vivo effects. Eur. J. Pharmacol., 222, 61-67.
22. Gouardères, C., Jhamandas, K., Sutak, M. & Zajac, J.-M. (1996a). Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Br. J. Pharmacol., 117, 493-501.
23. Gouardères, C., Kar, S. & Zajac, J.-M. (1996b). Presence of neuropeptide FF receptors on primary afferent libers of the rat spinal cord. Neurosci., 74, 21-27.
24. Gouardères, C., Sutak, M., Zajac, J.-M. & Jhamandas, K. (1993). Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. Eur. J. Pharmacol., 237, 73-81.
25. Gulya, K., Krivan, M., Nyolczas, N., Sarnyai, Z. & Kovacs, G.L. (1988). Central effects of the potent and the highly selective mu-opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur. J. Pharmacol., 150, 355-360.
26. 3H]CTOP), A potent and highly selective peptide for mu Opioid Receptors in rat brain. J. Pharmacol. Exp. Ther., 248, 73-80.
27. Hoffmann, O. & Wiesenfeld-Hallin, Z. (1994). The CCK-B receptor antagonist CI-988 reverses tolerance to morphine in rats. Neuroreport, 5, 2565-2568.
28. Idänpään-Heikkilä, J.J., Perrot, S., Guilbaud, G. & Kayser, V. (1997). In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Eur. J. Pharmacol., 325, 155-164.
29. Kauppila, T., Xu, X.J. & Wiesenfeld-Hallin, Z. (1998). Dextromethorphan potentiates the effect of morphine in rats with peripheral neuropathy. Neuroreport, 9, 1071-1074.
30. Kavaliers, M. (1990). Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide)-related peptides on nociception and morphine and stress-induced analgesia in mice. Neurosci. Lett., 115, 307-312.
31. Kayser, V., Lee, S.H. & Guilbaud, G. (1995). Evidence for a peripheral component in the enhanced antinociceptivc effect of a low dose of systemic morphine in rats with peripheral mononeuropathy. Neuroscience, 64, 537-545.
32. Kontinen, V.K., Aarnisalo, A.A., Idänpään-Heikkilä, J.J., Panula, P. & Kalso, E. (1997). Neuropeptide FF in the rat spinal cord during Carrageenan inflammation. Peptides, 18, 287-292.
33. 2-adrenergic and μ-opioid spinal antinociception by neuropeptide FF. Peptides, 16, 973-977.
34. Lee, S.H., Kayser, V., Desmeules, J. & Guilbaud, G. (1994). Differential action of morphine and various opioid agonists on thermal allodynia and hyperalgesia in mononeuropathic rats. Pain, 57, 233-240.
35. Mao, J., Price, D.D. & Mayer, D.J. (1995). Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain, 62, 259-274.
36. Mestre, C., Pelissier, T., Fialip, J., Wilcox, G. & Eschalier, A. (1994). A method to perform direct transcutaneous intrathecal injections in rats. J. Pharmacol. Toxicol. Methods, 32, 197-200.
37. Million, M., Fioramonti, J., Gicquel, S., Zajac, J.-M. & Bueno, L. (1993). Comparative action of Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 analogues on intestinal motility and nociception in rats. J. Pharmacol. Exp. Ther., 265, 96-102.
38. Nichols, M.L., Lopez, Y., Ossipov, M.H., Bian, D. & Porreca, F. (1997). Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve ligation model of peripheral neuropathy. Pain, 69, 317-322.
39. Ossipov, M.H., Lopez, Y., Nichols, M.L., Bian, D. & Porreca, F. (1995). Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett., 199, 83-86.
40. Qi, J.A., Bowen, W.D., Mosberg, H.I., Rothman, R.B. & Porreca, F. (1990). Opioid agonist and antagonist antinociceptive properties of (D-AIa2, Leu5, Cys6)enkephalin: selective actions at the delta noncomplexed site. J. Pharmacol. Exp. Ther., 255, 636-641.
41. Randall, L.O. & Selitto, J.J. (1957). A method for measurement of analgesic activity on inflammed tissue. Arch. Int. Pharmacodyn. 61, 409-419.
42. Raz, I. Hasdai, D., Seltzer, Z. & Melmed, R.N. (1988). Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes, 37, 1253-1259.
43. Roumy, M. & Zajac, J.-M. (1998). Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol., 345, 1-11.
44. Sora, I., Funada, M. & Uhl, G.R. (1997). The μ-opioid receptor is necessary for (D-Pen2, D-Pen)enkephalin-induced analgesia. Eur. J. Pharmacol., 324, R1-R2.
45. Stanfa, L., Dickenson, A.H., Xu, X.J. & Wiesenfeld-Hallin, Z. (1994). Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci., 15, 65-66.
46. Suh, H.W., Song, D.K., Wie, M.B., Jung, H.E., Choi, S.R. & Kim, Y.H. (1996). The reduction of antinociceptivc effect of morphine administered intaventricularly is correlated with the decrease of serotonin release from the spinal cord in streptozotocin-induced diabetic rats. Gen. Pharmacol., 27, 445-450.
47. Tallarida, R.J. (1992). Statistical analysis of drug combinations for synergism. Pain, 49, 93-97.
48. Traynor, J.R. & Elliott, J. (1993). δ-opioid receptor subtypes and cross-talk with μ-receptors. Trends Pharmacol. Sci., 14, 84-85.
49. Verge, V.M.K., Wiesenfeld-Hallin, Z. & Hökfelt, T. (1993). Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies on rat and monkey spinal ganglia. Eur. J. Neurosci., 5, 240-250.
50. Wei, H., Panula, P. & Pertovaara, A. (1998). A differential modulation of allodynia, hyperalgesia and nociception by neuropeptide FF in the periaqueducal gray of neuropathic rats: interactiond with morphine and naloxone. Neuroscience, 86, 311-319.
51. Xu, X.J., Puke, M.J., Verge, V.M., Wiesenfeld-Hallin, Z., Hughes, J. & Hökfelt, T. (1993). Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivily. Neurosci. Lett., 152, 129-132.
52. Yamamoto, T. & Yaksh, T.L. (1992). Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci. Lett., 135, 67-70.
53. Yang, H.-Y.T., Fratta, W., Majane, E.A. & Costa, E. (1985). Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. U.S.A., 82, 7757-7761.
54. Zhou, Y., Sun, Y.H., Zhang, Z.W., & Han, J.S. (1993). Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365, 260 in rat spinal cord. Eur. J. Pharmacol., 234, 147-154.
55. Zimmermann, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16, 109-110.